Literature DB >> 25904702

Melatonin pretreatment of human adipose tissue-derived mesenchymal stromal cells enhances their prosurvival and protective effects on human kidney cells.

Jing Zhao1, Yoon Kow Young1, Julie Fradette2, Nicoletta Eliopoulos3.   

Abstract

The efficacy of cell therapy for many diseases can be limited by the poor survival of implanted cells in an environment of tissue injury. Melatonin has been reported to have antioxidative and antiapoptotic effects. Adipose tissue-derived mesenchymal stromal cells (ASCs), cells easily obtained in high amounts and with minimal discomfort, have shown great promise in cell therapy applications, such as in acute kidney injury. We hypothesized that melatonin pretreatment of human ASCs (hASCs) would improve their renoprotective and prosurvival effects. We therefore investigated the action of melatonin on hASCs, as well as the effect of the resulting hASCs-conditioned media (CM) on human kidney cells exposed to oxidative and apoptotic injury-provoking doses of cisplatin. Our results demonstrated that pretreatment of hASCs with melatonin, 100 μM for 3 h, significantly increased their proliferation and their expression of prosurvival P-Erk1/2 and P-Akt, and of antioxidative enzymes catalase and heme oxygenase (HO)-1. In addition, the CM from hASCs pretreated with melatonin provoked a significantly higher proliferation and migration of HK-2 human kidney epithelial cells. Furthermore, this CM exerted significantly higher prosurvival and antiapoptotic actions on HK-2 cells exposed to cisplatin in vitro. Western blot analysis showed higher expression of P-Erk1/2, Bcl-2, SOD-1, and HO-1 in the HK-2 cells exposed to cisplatin in the presence of CM from melatonin-pretreated hASCs. In sum, our study revealed that in vitro pretreatment of hASCs with melatonin may significantly enhance their survival and their therapeutic effectiveness on injured tissue.
Copyright © 2015 the American Physiological Society.

Entities:  

Keywords:  adipose tissue; kidney cells; melatonin; mesenchymal stromal cells; stem cells

Mesh:

Substances:

Year:  2015        PMID: 25904702     DOI: 10.1152/ajprenal.00512.2014

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  7 in total

Review 1.  Elucidating the Regulatory Role of Melatonin in Brown, White, and Beige Adipocytes.

Authors:  Ziye Xu; Wenjing You; Jiaqi Liu; Yizhen Wang; Tizhong Shan
Journal:  Adv Nutr       Date:  2020-03-01       Impact factor: 8.701

Review 2.  Recent Updates on Mesenchymal Stem Cell Based Therapy for Acute Renal Failure.

Authors:  Asmaa Missoum
Journal:  Curr Urol       Date:  2020-01-07

Review 3.  Dietary Sources and Bioactivities of Melatonin.

Authors:  Xiao Meng; Ya Li; Sha Li; Yue Zhou; Ren-You Gan; Dong-Ping Xu; Hua-Bin Li
Journal:  Nutrients       Date:  2017-04-07       Impact factor: 5.717

4.  UM171A-induced ROS promote antigen cross-presentation of immunogenic peptides by bone marrow-derived mesenchymal stromal cells.

Authors:  Natasha Salame; Jean-Pierre Bikorimana; Nehme El-Hachem; Wael Saad; Mazen Kurdi; Jing Zhao; Nicoletta Eliopoulos; Riam Shammaa; Moutih Rafei
Journal:  Stem Cell Res Ther       Date:  2022-01-10       Impact factor: 6.832

Review 5.  Melatonin pretreatment on exosomes: Heterogeneity, therapeutic effects, and usage.

Authors:  Zilan Zhou; Ruiping Wang; Jie Wang; Yujia Hao; Qingpeng Xie; Lu Wang; Xing Wang
Journal:  Front Immunol       Date:  2022-09-16       Impact factor: 8.786

6.  Enhanced renoprotective effect of IGF-1 modified human umbilical cord-derived mesenchymal stem cells on gentamicin-induced acute kidney injury.

Authors:  Pengfei Liu; Yetong Feng; Delu Dong; Xiaobo Liu; Yaoyu Chen; Yi Wang; Yulai Zhou
Journal:  Sci Rep       Date:  2016-02-02       Impact factor: 4.379

Review 7.  Melatonin preconditioning is an effective strategy for mesenchymal stem cell-based therapy for kidney disease.

Authors:  Lingfei Zhao; Chenxia Hu; Ping Zhang; Hua Jiang; Jianghua Chen
Journal:  J Cell Mol Med       Date:  2019-11-20       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.